Trilexium  (Synonyms: TRX-E-009-1)

Trilexium (TRX-E-009-1) is a third-generation of benzopyran structurally related to TRX-E-002-1 (HY-114250). Trilexium increases p21 protein expression and induces apoptosis. Trilexium depolymerizes microtubules. Trilexium shows broad anti-cancer activity^[1][2].

Trilexium shows activity against a broad range of cancer types. Of the 240 cell lines assessed in the Eurofin’s Oncopanel, 10 cell lines shows IC₅₀ > 30 μM, of the remaining 230 cell lines, the average IC₅₀ is 0.428 μM^[1].
Trilexium (300 nM, 4 h) disrupts microtubule networks in Hela cells^[1].
Trilexium (1-5 μM) leads to increased protein expression of p21, c-PARP, and c-Caspase 3 in HSJD-DIPG007 cells^[2].
Trilexium (0-2 μM) restores H3K27 trimethylation and increases H3K27 acetylation in HSJD-DIPG007 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Trilexium (5-60 mg/kg, IV daily for 15 days) significantly reduces tumour volume in vivo^[1].
Trilexium (80 mg/kg, IV daily for 5 days) disrupts microtubules in vivo^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

426.43

C₂₄H₂₃FO₆

1983180-82-0

OC1=C(OC)C=C([C@H]2[C@@H](C3=CC(F)=C(C=C3)O)C4=CC=C(O)C(C)=C4OC2)C=C1OC

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Stevenson AJ, et al. Mechanism of action of the third generation benzopyrans and evaluation of their broad anti-cancer activity in vitro and in vivo. Sci Rep. 2018 Mar 23;8(1):5144.  [Content Brief]

  [2]. Ehteda A, et al. Microtubule-Targeting Combined with HDAC Inhibition Is a Novel Therapeutic Strategy for Diffuse Intrinsic Pontine Gliomas. Mol Cancer Ther. 2023 Dec 1;22(12):1413-1421.  [Content Brief]